GT Biopharma Inc (GTBP)
3.12
-0.15
(-4.59%)
USD |
NASDAQ |
May 17, 16:00
3.83
+0.71
(+22.76%)
After-Hours: 20:00
GT Biopharma Research and Development Expense (Quarterly): 1.357M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.357M |
| September 30, 2023 | 1.364M |
| June 30, 2023 | 2.095M |
| March 31, 2023 | 1.65M |
| December 31, 2022 | 2.842M |
| September 30, 2022 | 2.743M |
| June 30, 2022 | 1.139M |
| March 31, 2022 | 2.087M |
| December 31, 2021 | 6.304M |
| September 30, 2021 | 1.008M |
| June 30, 2021 | 0.639M |
| March 31, 2021 | 1.64M |
| December 31, 2020 | 0.233M |
| September 30, 2020 | -0.084M |
| June 30, 2020 | 0.012M |
| March 31, 2020 | 0.324M |
| December 31, 2019 | 0.008M |
| September 30, 2019 | 0.671M |
| June 30, 2019 | 0.154M |
| March 31, 2019 | 0.834M |
| December 31, 2018 | 1.232M |
| September 30, 2018 | 1.111M |
| June 30, 2018 | 3.251M |
| March 31, 2018 | 3.473M |
| December 31, 2017 | 0.157M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.526M |
| June 30, 2017 | 0.241M |
| March 31, 2017 | 0.144M |
| December 31, 2016 | 0.25M |
| September 30, 2016 | 0.25M |
| June 30, 2016 | 0.25M |
| March 31, 2016 | 0.225M |
| December 31, 2015 | 0.525M |
| September 30, 2015 | 0.225M |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.25M |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
| September 30, 2013 | 0.00 |
| June 30, 2013 | 0.00 |
| March 31, 2013 | 0.00 |
| December 31, 2012 | 0.00 |
| September 30, 2012 | 0.00 |
| June 30, 2012 | 0.00 |
| March 31, 2012 | 0.00 |
| December 31, 2011 | -0.032M |
| September 30, 2011 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-0.084M
Minimum
Sep 2020
6.304M
Maximum
Dec 2021
1.378M
Average
1.139M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| Cutera Inc | 5.001M |
| Outlook Therapeutics Inc | 13.51M |
| 180 Life Sciences Corp | -0.0364M |
| Journey Medical Corp | 7.884M |
| NovaBay Pharmaceuticals Inc | 0.019M |